Tecnotree Delivers Double-Digit Profit Growth and Accelerated Deployment Momentum in H1 2026

  ESPOO, Finland - Wednesday, 05. August 2026 AETOSWire 

(BUSINESS WIRE)--Tecnotree, a global leader in AI-native Digital Business Support Systems (BSS) and digital platform solutions for the telecommunications industry, today announced its financial results for the first half of 2026. The company delivered growth across every principal financial measure, expanded operating margin by 800 basis points, and converted a record order book into deployment at pace, with eight go-lives completed across the North America, Africa and the Middle East.

First Half (January – June 2026)

Net sales of EUR 36.8 million (EUR 34.2 million), up 7.5% year-on-year; in constant currency, EUR 37.6 million, up 10.0% year-on-year.

Operating result (EBIT) of EUR 13.2 million (EUR 9.6 million), up 38.1% year-on-year.

Operating margin of 36.0% (28.0%), up 800 bps year-on-year.

Net result of EUR 4.5 million (EUR 2.6 million), up 73.5% year-on-year.

Net income margin of 12.0% (7.0%).

Positive free cash flow of EUR 2.1 million (EUR 2.1 million), up 2.1% year-on-year.

Order book at the end of the period EUR 106.3 million (EUR 105.7 million), up 0.6% year-on-year.

Key Achievements

Eight Go-Lives Across North America, Africa and the Middle East: Tecnotree completed eight production deployments in the first half, converting order book into live operations. A Tier 1 North American operator went live across their enterprise and retail chains, a Middle East national operator simultaneously went live with Tecnotree’s combined B2B and B2C capabilities, and in Africa Tecnotree went live with six deployments spanning wholesale billing and settlement, onbiller, converged billing upgrades and a first-phase rollout with a major financial services institution.

New Customer Acquisitions and MVNX Expansion: Tecnotree added new customers across Latin America and Africa, deploying the AI-native digital B2B2X BSS, and Moments AI native realtime marketing and B2B marketplace platforms. Further, Tecnotree added Two Mobile Virtual Network Enabler (MVNX) engagements in Africa that now let operators launch virtual brands on a shared, cloud-native foundation in the region.

DevOps and Managed Services Growth: Tecnotree secured DevOps engagements across three operating companies of a leading pan-African operator group and one key Tier 1 customer in the Middle East, extending its role from platform provider to long-term operational partner.

Analyst Recognitions: Tecnotree was recognized across five Gartner® Hype Cycle™ reports through July 2026, reinforcing its relevance across critical CSP capabilities:

Hype Cycle for Autonomous Operations in the Communications Industry, 2026

Hype Cycle for Emerging Technologies in the Communications Industry, 2026

Hype Cycle for Telco Cloud Services, 2026

Hype Cycle for Enterprise Communication Services, 2026

Hype Cycle for Customer Experience and Monetization in the Communications Industry, 2026

Industry Awards: Tecnotree received nine analyst and industry recognitions through July 2026. Alongside the five Gartner Hype Cycle citations above, the company was named CX Catalyst Winner for Impact at The Fast Mode Awards and was included in The Fast Mode 100, both highlighting Tecnotree Moments CVM and XPM. At the Asian Telecom Awards 2026, Tecnotree won AI Initiative of the Year for the Moments Engagement and Experience Management platform, and Digital Initiative of the Year for its MVNE/MVNO CX Catalyst initiative built on Tecnotree BSS Suite 5.0.

Product Innovation: Tecnotree continued to enrich its platform with AI-native capabilities across Tecnotree Moments, Sensa and BSS Suite 5.0, advancing real-time decisioning, agentic orchestration and GenAI-driven customer engagement, alongside explainable AI governance for regulated telecom markets.

CEO Statement

Padma Ravichander, CEO of Tecnotree, stated: "Our H1 2026 results demonstrate that disciplined execution and AI-native innovation can grow together. Operating margin expanded by 800 basis points and net income rose by more than 70%, while we delivered eight go-lives across the North America, Africa and the Middle East — converting order book into live operations for our customers. What gives me the most confidence is the balance of this performance: new logos in Latin America and Africa, deeper DevOps partnerships in Africa and the Middle East, and MVNX expansion across the African market, all underpinned by a platform recognized across five Gartner Hype Cycle reports through July 2026. I am proud of our teams and partners, and we enter the second half of 2026 with strong momentum and a clear focus on sustained, profitable growth."

About Tecnotree

Tecnotree is a global leader in AI-native Digital BSS and fintech solutions, helping communications service providers accelerate digital transformation, monetize next-generation services and deliver exceptional customer experiences. With more than 40 years of industry expertise, Tecnotree serves operators across Europe, Asia, the Americas, Africa and the Middle East through its cloud-native, TM Forum Open Digital Architecture (ODA)-compliant platform. The company is listed on Nasdaq Helsinki (TEM1V).

Gartner® does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260805406933/en/

Permalink

https://www.aetoswire.com/en/news/5082026566100

Contacts

Further Information: Prianca Ravichander, CMO

Email: marketing@tecnotree.com www.tecnotree.com

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

 SAN CARLOS, Calif. - Wednesday, 05. August 2026 AETOSWire  

Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year

BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year

Diluted GAAP Earnings per American Depository Share (ADS) of $2.05 for the second quarter; non-GAAP diluted Earnings per ADS of $3.84 for the second quarter

Raised 2026 total revenue guidance to $6.6 to $6.8 billion; GAAP operating income of $1 to $1.1 billion, non-GAAP operating income of $1.7 to $1.8 billion

 

(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter of 2026.

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

“These strong second-quarter results underscore our continued growth as a global oncology leader. Our foundational hematology franchise, led by BRUKINSA, continues to gain momentum as we advance one of the industry’s deepest and most diverse pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well positioned for our next phase of global growth.”

Second Quarter 2026 Financial Results

Product Revenue totaled $1.7 billion for the second quarter of 2026, representing growth of 29% compared to the prior-year period.

BRUKINSA: Global sales totaled $1.2 billion for the second quarter of 2026, representing growth of 31% compared to the prior-year period; U.S. sales of BRUKINSA totaled $893 million in the second quarter of 2026, representing growth of 31% compared to the prior-year period.

TEVIMBRA (tislelizumab): Global sales totaled $229 million in the second quarter of 2026, representing growth of 18% compared to the prior-year period.

Amgen in-licensed products: Global sales totaled $157 million in the second quarter of 2026, representing growth of 25% compared to the prior-year period.

Gross Margin as a percentage of global product sales for the second quarter of 2026 was 90%, compared to 87% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company’s portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260805570642/en/

Permalink

https://www.aetoswire.com/en/news/54583421

Contacts

 

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com

TestMu AI Makes Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra Available on Real Device Cloud Ahead of Retail Launch

 Developers can test websites and mobile apps on Samsung's newest foldables, running Android 17, before the devices reach customers

 

(BUSINESS WIRE)--TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, announced that the Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra are now available for testing on its Real Device Cloud. Both devices, unveiled at Samsung's Galaxy Unpacked event, run Android 17 with One UI 9 and are accessible for live testing and automation before retail units reach customers.

The launch generation introduces a testing challenge new to the Galaxy Z Fold line. The Galaxy Z Fold8 unfolds into a portrait-oriented 7.6-inch display, while the Galaxy Z Fold8 Ultra, the first Ultra model in the Z series, unfolds into a landscape-oriented 8.0-inch display. Two devices that share a name, a chipset, and an operating system present layouts with opposite orientations, which means an interface validated on one can break on the other.

"Samsung has introduced two foldables with opposite unfolded orientations in the same generation, and that kind of form-factor diversity is exactly what engineering teams need to be ready for," said Mudit Singh, Co-Founder & Head of Growth, TestMu AI. "By making the Galaxy Z Fold8 and Z Fold8 Ultra available on Real Device Cloud before a single retail unit ships, we are giving teams a window to run their layout suites on both form factors, compare the results, and resolve defects before their users ever hold the hardware."

With the addition of the Fold8 pair, TestMu AI's Samsung foldable inventory spans four generations of the Galaxy Z Fold line across three Android versions, allowing teams to validate a single form factor against multiple OS releases. For web testing, each foldable presents two browser viewports, cover display and main display, giving teams four distinct viewports across the Fold8 pair to validate responsive layouts on real hardware. For mobile apps, the Real Device Cloud enables checks that emulators cannot replicate, including fold and unfold configuration changes, multi-window behavior, cover-screen entry points, and camera, biometric, and sensor behavior on the unfolded panel. Automation on both devices is supported through standard Appium capabilities.

"The gap between announcement and general availability is usually dead time for QA teams, because the hardware simply is not in anyone's hands," Singh added. "We want that gap to work in their favor. Every defect found on the Fold8 or Fold8 Ultra now is a defect their users will never see."

Additional details are available in the TestMu AI announcement blog.

About TestMu AI

TestMu AI (formerly LambdaTest) is a Full-Stack Agentic AI Quality Engineering platform that empowers teams to test intelligently and ship faster. Engineered for scale, it offers end-to-end AI agents to plan, author, execute, and analyze software quality. AI-native by design, the platform enables testing of web, mobile, and enterprise applications at any scale across real devices, real browsers, and custom real-world environments.

For more information, visit www.testmuai.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260805891281/en/

Permalink

https://aetoswire.com/en/news/5082026566144

Contacts

Media Contact

Nikhil Saxena

Corporate Communication Manager

TestMu AI

nikhils@testmuai.com

+919870981968

 

Bitget Launches Private Copy Trading for CFD

VICTORIA, Seychelles - Tuesday, 04. August 2026

(GLOBE NEWSWIRE) -- Bitget, the world’s largest Universal Exchange (UEX), has introduced Private Copy Trading for its CFD platform, giving professional traders the tools to build invitation-only trading communities while maintaining greater control over strategy distribution. The feature reflects the growing evolution of copy trading from a public discovery tool into a community-driven business model.

As copy trading has evolved, many successful traders have expanded beyond the platform itself, building dedicated communities across Telegram, Discord, X, and other social channels. These communities often become the primary way traders share market insights and cultivate long-term relationships. Rather than making every strategy publicly available, many now reserve their highest-conviction trades as exclusive benefits for members of those communities.

The feature introduces flexibility to community management, allowing traders to generate multiple invitation links for different communities or marketing channels, monitor conversion performance across each source, manage follower capacity independently, and remove followers when necessary. Public and private copy trading projects can also operate in parallel, enabling traders to grow a public audience while maintaining exclusive communities for selected users.

"As leaders of crypto copy trading, we’ve been one of the few players to evolve this segment" said Gracy Chen, CEO of Bitget. "Traders trust data and transparent copy-trading helps in collective growth, another tier added to this is private copy trading, providing professional traders with more flexibility in sharing strategies."

The invitation-only model also helps protect proprietary trading strategies by limiting visibility to approved participants rather than opening trading activity publicly. For traders focused on client acquisition, optional registration requirements tied to invitation links provide a more targeted way to onboard new users while measuring the effectiveness of different promotional channels.

Bitget pioneered copy trading as one of the first major exchanges to make professional trading strategies accessible to a broader audience. The launch reflects a broader evolution in the creator economy surrounding trading. As professional traders increasingly build independent brands and communities, copy trading platforms are evolving from simple discovery tools into infrastructure that supports audience management, client acquisition, and long-term community growth. Private Copy Trading extends Bitget's copy trading ecosystem to meet those changing needs.

To find out more, visit here.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships such as MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | X | Telegram | LinkedIn | Discord

For media inquiries, please contact: media@bitget.com

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c75a0757-6ad4-4e1b-a9b9-fbd222b85dba

New 3D Flash Memory Technology from Kioxia and Sandisk Achieves Industry’s Highest Bit Density for QLC NAND

 10th-generation QLC 3D flash memory represents a major leap forward for AI storage architectures, cloud platforms, and data‑intensive innovations

 

(BUSINESS WIRE)--Future of Memory and Storage Conference (FMS) – Kioxia Corporation, a subsidiary of Kioxia Holdings Corporation (TOKYO: 285A) and Sandisk Corporation (Nasdaq: SNDK) today unveiled their next-generation Quad-Level-Cell (QLC) 3D flash memory technology, which delivers up to 60% increase in bit density compared to their 8th-generation, surpassing 37 Gb/mm² and setting the industry benchmark1 for bit density, performance and power efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804147821/en/

Leveraging the companies’ revolutionary CMOS directly Bonded to Array (CBA) technology2 which fabricates CMOS logic and the memory array on separate wafers before bonding them together with high-precision wafer-to-wafer alignment, the new generation improves read and write bandwidth compared to the 8th-generation 3D flash memory and becomes the industry’s first QLC 3D flash memory technology to reach a 4.8 Gb/s 3 interface.

Additional interface enhancements improve I/O data-out transfer power efficiency. These large power efficiency upgrades directly address the power and cooling challenges of modern AI and cloud infrastructure.

Chief Technology Officer at Kioxia, Hideshi Miyajima, said, “As AI continues to underpin the advancement of society, its applications are expanding from generative AI to agent-based and physical AI, while the use of data is becoming increasingly diverse and sophisticated. QLC technology enables the efficient storage of rapidly expanding data volumes, helping deliver greater performance and scalability for AI systems. Kioxia will accelerate development toward the commercialization of its 10th-generation flash memory products incorporating QLC technology.”

Chief Technology Officer at Sandisk, Alper Ilkbahar, said, "As AI training, inference, and hyperscale datacenter workloads drive unprecedented growth in data generation, the storage industry faces increasing pressure to deliver greater capacity, higher performance, and improved energy efficiency. By redefining the performance and efficiency envelope of QLC NAND, our 10th-generation QLC 3D flash memory delivers simultaneous gains in density, bandwidth, and energy efficiency and establishes a new paradigm for high‑capacity flash storage to provide a scalable foundation for next‑generation infrastructure applications.”

Key 10th-genaration QLC 3D flash memory technology highlights include:

332‑layer architecture and optimized floorplan design deliver up to 60% increase in bit density, achieving >37 Gb/mm² compared to the 8th-generation.

4.8 Gb/s 3 NAND interface enabled by Toggle DDR6.0 and the Separate Command Address (SCA) protocol to unlock the full potential of fast interface.

CMOS directly Bonded to Array (CBA) architecture enhances density scaling, performance, and manufacturing efficiency.

Power‑Isolated Low‑Tapped Termination (PI‑LTT) improves I/O data-out transfer power efficiency.

As of August 4, 2026, based on Kioxia and Sandisk survey.

Technology wherein each CMOS wafer and cell array wafer are manufactured separately in their optimized condition and then bonded together.

1Gb/s is calculated as 1,000,000,000 bits/second. This value is obtained under our specific test environment, and may vary depending on use conditions.

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems.

About Sandisk

Sandisk (Nasdaq: SNDK) delivers innovative Flash solutions and advanced memory technologies that meet people and businesses at the intersection of their aspirations and the moment, enabling them to keep moving and pushing possibility forward. Follow Sandisk on Instagram, Facebook, X, LinkedIn, YouTube. Join TeamSandisk on Instagram.

Sandisk and the Sandisk logo are registered trademarks or trademarks of Sandisk Corporation or its affiliates in the US and/or other countries. All other marks are the property of their respective owners. Product specifications subject to change without notice. Pictures shown may vary from actual products.

© 2026 Sandisk Corporation or its affiliates. All rights reserved.

Company names, product names and service names may be trademarks of their respective companies.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of U.S. federal securities laws, including statements regarding expectations for the performance, capabilities, improved power efficiency, bit density and scalability of Sandisk Corporation’s and Kioxia Corporation’s BiCS10 QLC technology; the expected growth of AI training, inference, and hyperscale datacenter workloads and the resulting demand for growth in data generation; the anticipated benefits of the BiCS10 QLC architecture for modern AI, cloud infrastructure, hyperscale data centers, and enterprise storage applications; and the anticipated industry significance and competitive positioning of the technology. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Key risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements include: adverse changes in global or regional economic conditions, including the impact of evolving trade policies, tariff regimes and trade wars; volatility in demand for Sandisk’s products; pricing trends and fluctuations in average selling prices; exposure to execution, financial and market risks due to long-term agreements; inflation; changes in interest rates and a potential economic recession; the impact of business and market conditions; the impact of competitive products and pricing; the development and introduction of products based on new technologies and management of technology transitions; risks associated with strategic initiatives, including restructurings, acquisitions, divestitures, cost saving measures and joint ventures; risks related to product defects; difficulties or delays in manufacturing or other supply chain disruptions; reliance on strategic relationships with key partners, including Kioxia Corporation; the attraction, retention and development of skilled management and technical talent; risks associated with the use of artificial intelligence in business operations; changes to relationships with key customers or consolidation among the customer base; compromise, damage or interruption from cybersecurity incidents or other data system security risks; reliance on intellectual property; fluctuations in currency exchange rates; actions by competitors; risks associated with compliance with changing legal and regulatory requirements; and other risks and uncertainties listed in Sandisk’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed with the SEC on August 21, 2025 and Quarterly Report on Form 10-Q filed with the SEC on May 1, 2026, to which your attention is directed. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Sandisk undertakes no obligation to update or revise these forward-looking statements to reflect new information or events, except as required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804147821/en/

Permalink

https://aetoswire.com/en/news/4082026565999

Contacts

Sandisk Contacts:

Investors: investors@sandisk.com

Media: mediainquiries@sandisk.com

Kioxia Contact:

Media: kioxia-hd-pr@kioxia.com

 

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership

BOSTON - Tuesday, 04. August 2026

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership.

(BUSINESS WIRE)--WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control.

The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app also supports users through pregnancy planning, pregnancy, postpartum, and perimenopause with dedicated modes tailored to each stage of their reproductive journey.

This integration and exclusive offer advance the efforts of WHOOP in women’s health by combining continuous physiological data with clinically validated fertility technology. Women are one of the fastest-growing segments of WHOOP members, with membership growing 111% year over year. As demand grows for personalized health insights and non-hormonal reproductive health options, this integration gives WHOOP members a more seamless way to understand fertility alongside the recovery, sleep, and health insights already available through WHOOP.

"This partnership represents a commitment to supporting women's health through clinically-backed, actionable data," said Dr. Ami Bhatt, WHOOP Chief Medical Officer. "By integrating with the NC° app, we are providing our members with a seamless way to access personalized reproductive health insights, expanding WHOOP beyond performance into everyday health."

"At Natural Cycles, we're committed to making digital contraception as seamless as possible for our users," said Dr. Magda Armbruster, VP of Product at Natural Cycles. "Integrating with WHOOP removes friction from the experience by allowing members to use the wearable they already rely on to automatically capture overnight skin temperature used by the NC° app to determine daily fertility status. It's another step toward making hormone-free birth control fit more naturally into everyday life."

Membership Benefits:

A 12-month subscription to the NC° app included with any WHOOP membership for members new to Natural Cycles.

Automatic overnight skin temperature sharing with the NC° app through compatible WHOOP devices.

Daily fertility status inside the world's only FDA-cleared digital birth control app.

Features designed by Natural Cycles° to support women throughout the reproductive journey—from birth control and pregnancy planning to pregnancy, postpartum, and perimenopause.

The integration is currently available for users with WHOOP MG and 5.0 devices. WHOOP and Natural Cycles° remain committed to the highest standards of privacy and data security, ensuring that sensitive health information is managed with the utmost care.

To learn more about WHOOP, please visit whoop.com. To access visuals, please visit the Digital Press Kit.

About WHOOP

WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and longevity. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Research shows that people who wear WHOOP daily log more than 90 additional minutes of exercise per week, get over two extra hours of sleep, and have 10% higher heart rate variability.

Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $950 million in venture capital, ships to 56 countries, and operates in six languages. To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.

About Natural Cycles°

Founded in 2013 by physicists Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles is a leading women's digital health company dedicated to transforming how women understand and manage their reproductive health. The company developed the world's first FDA-cleared digital method of birth control, delivered through an app and powered by a proprietary algorithm that interprets biomarker data, including body temperature, to provide personalized cycle insights and a daily fertility status. The NC° Birth Control app is an FDA-cleared Class II medical device with six FDA clearances and has also received regulatory authorizations in Europe, Canada, Brazil, Australia, Singapore, and South Korea.

With a single subscription, the Natural Cycles app offers five dedicated modes—NC° Birth Control, NC° Plan Pregnancy, NC° Follow Pregnancy, NC° Postpartum, and NC° Perimenopause—supporting women throughout their reproductive lives. Trusted by more than six million registered users worldwide and backed by 30 peer-reviewed studies, Natural Cycles continues to pioneer science-driven, non-invasive innovations that expand access to personalized reproductive health tools and empower women to take control of their reproductive health.

Learn more at Naturalcycles.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804399367/en/

Permalink

https://www.aetoswire.com/en/news/54582456

Contacts

 

Press Contact

Jack Taylor Worldwide

Whoop@jacktaylorpr.com

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care

 SAN DIEGO - Tuesday, 04. August 2026 AETOSWire Print 

(BUSINESS WIRE)--LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3

KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5

The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The first FDA approval of a menin inhibitor for relapsed or refractory acute leukemia with a KMT2A translocation established clinical validation for this emerging drug class.7 As menin inhibitor programs move into frontline and combination studies, there is an increasing need for sensitive molecular testing that can accurately characterize KMT2Ar, quantify deep molecular response, and track response durability over time.

Standardized MRD Testing for Global Clinical Development

LabPMM’s new test targets the most common KMT2A partner fusion genes in AML and ALL,8 aligning the assay with the KMT2A biology central to many current menin inhibitor development programs. The test provides a quantitative result reported as the percentage of KMT2Ar relative to a housekeeping gene. The assay supports disease characterization and longitudinal MRD monitoring with sensitivity down to 0.005% and a turnaround time in as little as 48 hours.9 This launch expands Invivoscribe’s comprehensive myeloid testing portfolio, which includes globally standardized molecular assay kits and LabPMM services for screening and MRD monitoring of FLT3, NPM1, KMT2Ar, as well as AML MRD assessment by multiparametric flow cytometry. Together, these integrated capabilities enable drug developers and healthcare providers to monitor disease burden over time with unprecedented sensitivity and accuracy.

“Menin inhibitors are creating important new possibilities for patients with KMT2A-rearranged leukemia, but continued development requires a partner that can deliver highly sensitive, standardized molecular data across clinical programs and geographies,” said Jeff Miller, CEO and CSO of Invivoscribe. “By making KMT2A MRD testing available through LabPMM, we are helping clinicians and biopharmaceutical partners measure meaningful responses earlier, monitor their durability, and ultimately improve patient care.”

Together, Invivoscribe and LabPMM provide an integrated global ecosystem of standardized MRD testing, regulatory expertise, and companion diagnostic capabilities. Highly sensitive MRD testing can help define molecular response depth, evaluate response durability, support patient stratification, and accelerate trials when used as surrogate endpoints. By generating consistent molecular data across global clinical programs, this integrated approach helps sponsors make earlier, more informed decisions and reduce development risk from early clinical studies through regulatory submission, approval, and commercialization.

Healthcare providers and biopharmaceutical sponsors developing menin inhibitors for acute leukemia or other immunotherapies can contact Invivoscribe to discuss our global testing programs. Visit www.invivoscribe.com or contact inquiry@invivoscribe.com

About Invivoscribe

Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For over thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high-quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan, and China, and in developing and commercializing companion diagnostics, with rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries, LabPMM®, Invivoscribe is an ideal partner from diagnostic development through clinical trials, regulatory submissions, and commercialization.

References

Dillon, L. et al. JAMA Oncol. 2024;10;(8):1104-1110. https://doi.org/10.1001/jamaoncol.2024.0985

Levis, M., et al. Blood. 2025;145(19):2138-2148 https://doi.org/10.1182/blood.2024025154

Hourigan CS, et al. Blood. 2025;145(19)2105-2106. https://doi.org/10.1182/blood.2024028105

Petersen, L. et al. J Mol Diag. 2025;27(10)989-1002. https://doi.org/10.1016/j.jmoldx.2025.06.007

Yin, L. et al. Cancer Med. 2024;13(20):e70326. https://doi.org/10.1002/cam4.70326

Al-Ali, R. et al. Bone Marrow Transplant. 2025;61:222-224. https://doi.org/10.1038/s41409-025-02757-1

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-KMT2A-translocation

Additional KMT2A partner fusion genes will be added in early 2027 further expanding ALL coverage.

MRD results from our KMT2A, FLT3-ITD, and NPM1 assays can be reported in as little as 48 hours, although standard turnaround time is 7-10 business days.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260803738654/en/

Permalink

https://www.aetoswire.com/en/news/54582770

Contacts

 

inquiry@invivoscribe.com

1-866-623-8105